Oncolytics Biotech is seeking accelerated approval for its lead cancer therapy, pelareorep, with plans to start a ...

Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to ...

Johnson & Johnson has bought oncolytic immunotherapy biotech BeneVir, adding immune-oncology drugs to a cancer pipeline dominated by antibodies and small molecules. Benevir uses proprietary ...

Virus is associated with sickness, but oncolytic virus therapies, which harness viruses to attack and kill cancer cells, may soon change the standard of treatment for cancer, including those long ...

KaliVir Immunotherapeutics has dosed the first subject in a Phase I/Ib clinical trial for its new oncolytic immunotherapy, ...

Aiding the immune response in the fight against cancer, TILT Biotherapeutics is developing armed oncolytic viruses that replicate in cancer cells making them more discoverable by T cells and other ...

A new review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, "Zika virus and brain cancer: Can Zika ...

CLD-101 is a novel stem cell-based treatment that delivers oncolytic viruses to tumors, which may benefit patients with newly ...

因此，惟亚德生物团队利用重组溶瘤病毒在TME所高效表达的特异性蛋白，来纠正脂质紊乱并抑制促肿瘤炎症。目前首个管线产品重组NV-A01腺病毒注射液针对三阴乳腺癌、晚期肝癌及其他恶性实体肿瘤的适应症已进入Ⅰ期临床试验；与此同时，团队完成了在复发的高级别脑 ...

WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and ...